In recent years, the use of adaptive design methods has become very popular due to its flexibility for identifying clinical benefits of the testing drug. Adaptive designs offer the potential to reduce timelines and patient exposure while maximising the probability for successful outcomes. However, along with these benefits come challenges: additional complexity, needs for advanced statistical models and increased operational demands.
The 8th annual Adaptive Clinical Trials conference is designed to highlight an array of topics, including adaptive designs within the context of a development programme, Bayesian analysis in adaptive design, biomarker-driven trials, regulatory issues associated with adaptive design, and more.
A series of practical case studies, interactive roundtables and panel discussion facilitated by leading industry experts will provide executives with useful tools and best practices to:
Explore the use of adaptive design methods in clinical trials
Adapt clinical development for immunotherapies in oncology
Evaluate adaptive designs and Bayesian statistic
Improve covariant adaptive designs
Seamless Phase I/II Dose Finding Designs with Efficacy and Safety Endpoints
Expert Speaker Panel includes:
Bo Huang, Director of Biostatistics, Pfizer USA
Alex Sverdlov, Associate Director of Biostatistics, EMD Serono
Lo茂c Darchy, Head of Statistical Methodology Group, Sanofi RandD
Philip Hougaard, Vice President, Biometrics, Lundbeck A/S
Giacomo Mordenti, Senior Director, Head of Biostatistics, Grunenthal
Bruce Turnbull, Professor of Statistics, Cornell University
Don't miss out an interactive post-conference workshop: Design, Analysis and Simulation of Adaptive Clinical Trials Using ADDPLAN (Led by ICON plc)
For further information/to register please get in touch with Matthew Apps: +44 20 7827 6093 / mapps@smi-online.co.uk
Alternatively, visit the events website: www.adaptivedesigns.co.uk
The 8th annual Adaptive Clinical Trials conference is designed to highlight an array of topics, including adaptive designs within the context of a development programme, Bayesian analysis in adaptive design, biomarker-driven trials, regulatory issues associated with adaptive design, and more.
A series of practical case studies, interactive roundtables and panel discussion facilitated by leading industry experts will provide executives with useful tools and best practices to:
Explore the use of adaptive design methods in clinical trials
Adapt clinical development for immunotherapies in oncology
Evaluate adaptive designs and Bayesian statistic
Improve covariant adaptive designs
Seamless Phase I/II Dose Finding Designs with Efficacy and Safety Endpoints
Expert Speaker Panel includes:
Bo Huang, Director of Biostatistics, Pfizer USA
Alex Sverdlov, Associate Director of Biostatistics, EMD Serono
Lo茂c Darchy, Head of Statistical Methodology Group, Sanofi RandD
Philip Hougaard, Vice President, Biometrics, Lundbeck A/S
Giacomo Mordenti, Senior Director, Head of Biostatistics, Grunenthal
Bruce Turnbull, Professor of Statistics, Cornell University
Don't miss out an interactive post-conference workshop: Design, Analysis and Simulation of Adaptive Clinical Trials Using ADDPLAN (Led by ICON plc)
For further information/to register please get in touch with Matthew Apps: +44 20 7827 6093 / mapps@smi-online.co.uk
Alternatively, visit the events website: www.adaptivedesigns.co.uk
